CA3231639A1 - Triple-agent therapy for cancer treatment - Google Patents

Triple-agent therapy for cancer treatment Download PDF

Info

Publication number
CA3231639A1
CA3231639A1 CA3231639A CA3231639A CA3231639A1 CA 3231639 A1 CA3231639 A1 CA 3231639A1 CA 3231639 A CA3231639 A CA 3231639A CA 3231639 A CA3231639 A CA 3231639A CA 3231639 A1 CA3231639 A1 CA 3231639A1
Authority
CA
Canada
Prior art keywords
cancer
gefitinib
tamoxifen
regimen
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3231639A
Other languages
English (en)
French (fr)
Inventor
Larry Weisenthal
William Grace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytometric Therapeutics Inc
Original Assignee
Cytometric Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytometric Therapeutics Inc filed Critical Cytometric Therapeutics Inc
Publication of CA3231639A1 publication Critical patent/CA3231639A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3231639A 2021-09-15 2022-09-15 Triple-agent therapy for cancer treatment Pending CA3231639A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163244412P 2021-09-15 2021-09-15
US63/244,412 2021-09-15
PCT/US2022/043601 WO2023043883A1 (en) 2021-09-15 2022-09-15 Triple-agent therapy for cancer treatment

Publications (1)

Publication Number Publication Date
CA3231639A1 true CA3231639A1 (en) 2023-03-23

Family

ID=85603487

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3231639A Pending CA3231639A1 (en) 2021-09-15 2022-09-15 Triple-agent therapy for cancer treatment

Country Status (10)

Country Link
US (1) US12611411B2 (https=)
EP (1) EP4401720A4 (https=)
JP (1) JP2024531765A (https=)
KR (1) KR20240060625A (https=)
CN (1) CN118159262A (https=)
AU (1) AU2022345084A1 (https=)
CA (1) CA3231639A1 (https=)
IL (1) IL311229A (https=)
MX (1) MX2024003333A (https=)
WO (1) WO2023043883A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2644194T3 (en) * 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
US20100189683A1 (en) 2008-11-14 2010-07-29 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
KR101874390B1 (ko) * 2013-09-26 2018-07-04 파이브3 제노믹스, 엘엘씨 바이러스-연관 종양을 위한 시스템, 방법, 및 조성물

Also Published As

Publication number Publication date
JP2024531765A (ja) 2024-08-29
EP4401720A4 (en) 2025-07-30
CN118159262A (zh) 2024-06-07
IL311229A (en) 2024-05-01
MX2024003333A (es) 2024-05-20
US20250127791A1 (en) 2025-04-24
WO2023043883A1 (en) 2023-03-23
US12611411B2 (en) 2026-04-28
AU2022345084A1 (en) 2024-03-28
EP4401720A1 (en) 2024-07-24
KR20240060625A (ko) 2024-05-08

Similar Documents

Publication Publication Date Title
Morabito et al. Treatment of small cell lung cancer
Safran et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity
Pinto et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
TWI630924B (zh) 使用包含微脂體伊立替康（ｉｒｉｎｏｔｅｃａｎ）的組合療法治療胰臟癌的方法
WO2021098679A1 (zh) Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途
US8383607B2 (en) Perifosine and capecitabine as a combined treatment for cancer
US11369585B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
BR112017028287A2 (en) COMBINATION OF THE HDAC INHIBITOR AND ANTICORPIDE ANTI-PD- L1 FOR CANCER TREATMENT
US12213958B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
Kelley et al. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206
KR20140040728A (ko) Pi3k 억제제 화합물을 사용한 중피종 치료 방법
CN107427522A (zh) 用于治疗黑素瘤的阿吡莫德
US20260053791A1 (en) Use of tivozanib to treat subjects with refractory cancer
CN108135892A (zh) 用于治疗癌症的mdm2抑制剂的给药方案
Anampa et al. Phase I trial of veliparib, a poly ADP ribose polymerase inhibitor, plus metronomic cyclophosphamide in metastatic HER2-negative breast cancer
JP2019112416A (ja) 癌の処置方法
Ando et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer
US20110159080A1 (en) Composition comprising liposome-entrapped doxorubicin and methods of administration
US12611411B2 (en) Triple-agent therapy for cancer treatment
EP3456354A1 (en) New anti-malignant tumor agent based on specificity of cancer cell metabolism
JP2009509974A (ja) 抗癌治療
Hernandez-Aya 13 Skin Cancer
AU2023351704A1 (en) Compositions for the treatment and prevention of cancer
WO2025059579A1 (en) Methods of treating mat2a related diseases
CN118924750A (zh) 吡啶胺化合物在经克唑替尼治疗后耐药的非小细胞肺癌中的应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250909

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250909